Eris Lifesciences Limited (NSE:ERIS)
India · Delayed Price · Currency is INR | Market Cap | 192.65B -18.0% |
| Revenue (ttm) | 32.12B +9.4% |
| Net Income | 6.44B +66.6% |
| EPS | 46.85 +65.2% |
| Shares Out | 138.57M |
| PE Ratio | 29.67 |
| Forward PE | 29.48 |
| Dividend | 7.21 (0.52%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 340,891 |
| Open | 1,393.00 |
| Previous Close | 1,393.40 |
| Day's Range | 1,379.00 - 1,410.00 |
| 52-Week Range | 1,200.00 - 1,820.00 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 1,661.20 (+20.38%) |
| Earnings Date | Jul 29, 2026 |
About Eris Lifesciences
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electro... [Read more]
Financial Performance
In fiscal year 2026, Eris Lifesciences's revenue was 31.15 billion, an increase of 8.18% compared to the previous year's 28.79 billion. Earnings were 6.20 billion, an increase of 76.08%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ERIS stock is "Strong Buy." The 12-month stock price target is ₹1,661, which is an increase of 20.38% from the latest price.
News
Eris Lifesciences Transcript: Q1 26/27
Q1 saw 14% revenue growth in domestic formulations and 13% consolidated revenue growth year-over-year, with strong insulin and semaglutide performance. Gross margins contracted due to product mix, but improvement is expected as the Bhopal facility ramps up. EBITDA margin stood at 35%.
Eris Lifesciences Slides: Q1 2027
Eris Lifesciences has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 29, 2026.
Eris Lifesciences Quarterly report: Q1 2027
Eris Lifesciences has published its Q1 2027 quarterly earnings report on July 29, 2026.
Eris Lifesciences Slides: Corporate presentation
Eris Lifesciences has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Eris Lifesciences achieves top-5 market position in anti-diabetes therapy
Eris Lifesciences has secured a top-5 market position in the anti-diabetes therapy sector, boasting a 6% market share. The company, which is among the top-20 Indian pharmaceutical companies in less…
Eris Lifesciences pays Rs 54.56 crore interest on outstanding debentures
Eris Lifesciences has confirmed the payment of ₹54.56 crore in interest to holders of its non-convertible debentures (NCDs) as part of routine servicing of outstanding debt. This payment aligns with…
Eris Lifesciences Transcript: Q4 25/26
Domestic and consolidated revenues grew 11% and 8% respectively, with strong insulin and derma segment performance and rapid semaglutide uptake. Regulatory delays and supply chain issues impacted some launches and international shipments, but margin guidance and capital efficiency are expected to improve.
Eris Lifesciences Slides: Q4 2026
Eris Lifesciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 20, 2026.
Eris Lifesciences Quarterly report: Q4 2026
Eris Lifesciences has published its Q4 2026 quarterly earnings report on May 20, 2026.
Top gainers today: eris lifesciences at ₹1,458.20 up 9.13%, Tata communications at ₹1,775.60 up 7.83%, balaji amines at ₹1,833.30 up 7.29%
The Indian stock market exhibited a positive trend today, with the Sensex rising to 75,318.39, marking a 0.16% increase, and the Nifty 50 climbing to 23,659.00, up by 0.17%. Among…
Eris Lifesciences faces procedural non-compliance at Swiss Parenterals units
Eris Lifesciences has announced that its Swiss Parenterals Units 1 and 2 in Ahmedabad, Gujarat, have been inspected by HALMED, the Agency for Medicinal Products and Medical Devices of Croatia,…
Eris Lifesciences completes acquisition of Velbiom Probiotics business
Eris Lifesciences has successfully completed the acquisition of the probiotics business from Velbiom Probiotics Private Limited. This marks the closure of a transaction initially announced on 20 March...
Eris Lifesciences partners with Natco Pharma for semaglutide launch in India
Eris Lifesciences Limited has announced a strategic partnership with Natco Pharma Limited to commercialise Semaglutide in India. This move aims to bolster Eris's leadership in the rapidly expanding di...
Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India
Eris Lifesciences Limited has entered into a strategic partnership with Natco Pharma Limited for the commercialisation of semaglutide in India,...
Eris Lifesciences Slides: Corporate presentation
Eris Lifesciences has posted slides in relation to its latest quarterly earnings report, which was published on February 20, 2026.
Eris Lifesciences Transcript: Q3 25/26
Q3 and nine-month results showed double-digit revenue and profit growth, margin expansion, and strong market share gains in insulins and cardiac care. Strategic launches, discontinuation of non-core brands, and robust CDMO order book position the company for continued growth and margin improvement.
Eris Lifesciences Quarterly report: Q3 2026
Eris Lifesciences has published its Q3 2026 quarterly earnings report on February 13, 2026.
Eris Lifesciences Slides: Q3 2026
Eris Lifesciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Eris Lifesciences Q3 Results: Revenue jumps 10% YoY to Rs 807 crore, net profit up 19%
Eris Lifesciences reported a steady set of numbers for the third quarter, with profit and operating performance showing year-on-year growth....
Eris Lifesciences Transcript: Q2 25/26
Q2 saw 10% domestic revenue growth and 11% EBITDA growth, with Biocon margins rising to 32%. International business expanded, and the European CDMO order book reached INR 700-800 crore. CapEx is front-loaded, with net debt-to-EBITDA expected below 1.5x by Dec 2026.
Eris Lifesciences Quarterly report: Q2 2026
Eris Lifesciences has published its Q2 2026 quarterly earnings report on November 12, 2025.
Eris Lifesciences Slides: Q2 2026
Eris Lifesciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
Eris Lifesciences Q2 Results: Net profit jumps 31% YoY to Rs 120 crore, revenue up 6.3%
Eris Lifesciences Limited reported a strong performance for the second quarter of FY26, with a healthy rise in profitability and...
Eris Lifesciences secures ANVISA approval for Ahmedabad sterile injectable facility
Eris Lifesciences Limited on Tuesday announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from ANVISA, Brazil’s national health regulatory agency. T...
Eris Lifesciences secures approval from ANVISA for Ahmedabad facility
Eris Lifesciences Limited (BSE: 540596, NSE: ERIS), one of India’s leading branded formulations companies, announced that a manufacturing unit at its Ahmedabad campus has received approval from ANVISA...